Login

Switch On Your HIV Smarts.

Biktarvy, a new HIV combo pill recently approved by the FDA

Biktarvy, a new HIV combo pill recently approved by the FDA

, by Jennifer Cocohoba, PharmD, AAHIVE

This week, the FDA granted approval of Gilead Science’s single-table combo pill of bictegravir, emtricitabine, and tenofovir alafenamide named Biktarvy. Read More

Who knows about U=U? Awareness that undetectable individuals do not transmit HIV increasing, says new study

Who knows about U=U? Awareness that undetectable individuals do not transmit HIV increasing, says new study

, by Emily Land

The message of undetectable = untransmittable is empowering, but not everyone has heard it. New research investigates who’s getting the message, and who is being left behind. Read More

Why do some HIV drugs cost so much? Pharma, insurers, advocacy groups and consumers weigh in

Why do some HIV drugs cost so much? Pharma, insurers, advocacy groups and consumers weigh in

, by Emily Land

Drug pricing is a complicated issue, with pharmaceutical companies on one side, patient activists on the other, and consumers oftentimes stuck somewhere in the middle. Read More

For people with HIV, what’s next after viral suppression?

For people with HIV, what’s next after viral suppression?

, by Emily Land

Improving quality of life—in addition to helping people get to undetectable—can be a focus of health care models that serve people living with HIV. Read More

Magic mushrooms as therapy for long-term HIV survivors?

Magic mushrooms as therapy for long-term HIV survivors?

, by Emily Land

A small study with long-term HIV survivors in San Francisco will investigate whether an experimental treatment with psilocybin and group therapy can be used to improve mental health and emotional well-being. Read More